Current therapies for tissue regeneration rely on the presence or direct delivery of growth factors to sites of repair. Bone morphogenetic protein-2 (BMP-2), combined with a carrier (usually collagen), is clinically proven to induce new bone formation during spinal fusion and nonunion repair. However, due to BMP-2's short half-life and its diffusive properties, orders of magnitude above physiological levels are required to ensure effectiveness. In addition, a high dose of this multifunctional growth factor is known to induce adverse effects in patients. To circumvent these challenges, we proposed and tested a new approach for BMP-2 delivery, by controlling BMP activity via carrier binding and localized proteolysis. BMP-2 was covalently bound to gelatin through site-specific enzymatic crosslinking using a microbial transglutaminase. Binding of BMP-2 to gelatin can completely switch off BMP-2 activity, as evidenced by loss of its transdifferentiating ability toward C2C12 promyoblasts. When gelatin sequestered BMP-2 is incubated with either microbial collagenase or tissue-derived matrix metalloproteinases, BMP-2 activity is fully restored. The activity of released BMP-2 correlates with the protease activity in a dose- and time-dependent manner. This observation suggests a novel way of delivering BMP-2 and controlling its activity. This improved delivery method, which relies on a physiological feedback, should enhance the known potential of this and other growth factors for tissue repair and regeneration.
Get full access to this article
View all access options for this article.
References
1.
KugimiyaF., KawaguchiH., KamekuraS., ChikudaH., OhbaS., YanoF., OgataN., KatagiriT., HaradaY., AzumaY., NakamuraK., ChungU.I.Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. J Biol Chem, 280:35704. 2005.
2.
UristM.R.Bone: formation by autoinduction. Science, 150:893. 1965.
3.
WangE.A., IsraelD.I., KellyS., LuxenbergD.P.Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors, 9:57. 1993.
4.
SuzawaM., TakeuchiY., FukumotoS., KatoS., UenoN., MiyazonoK., MatsumotoT., FujitaT.Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology, 140:2125. 1999.
5.
KatagiriT., YamaguchiA., KomakiM., AbeE., TakahashiN., IkedaT., RosenV., WozneyJ.M., Fujisawa-SeharaA., SudaT.Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol, 127:1755. 1994.
6.
YamaguchiA., KatagiriT., IkedaT., WozneyJ.M., RosenV., WangE.A., KahnA.J., SudaT., YoshikiS.Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol, 113:681. 1991.
7.
OtsuruS., TamaiK., YamazakiT., YoshikawaH., KanedaY.Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells, 26:223. 2008.
8.
SampathT.K., MaliakalJ.C., HauschkaP.V., JonesW.K., SasakH., TuckerR.F., WhiteK.H., CoughlinJ.E., TuckerM.M., PangR.H.et al.Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem, 267:20352. 1992.
9.
WangE.A., RosenV., D'AlessandroJ.S., BauduyM., CordesP., HaradaT., IsraelD.I., HewickR.M., KernsK.M., LaPanP.et al.Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A, 87:2220. 1990.
10.
BurkusJ.K., SandhuH.S., GornetM.F., LongleyM.C.Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am, 87:1205. 2005.
11.
VaccaroA.R., AndersonD.G., PatelT., FischgrundJ., TruumeesE., HerkowitzH.N., PhillipsF., HilibrandA., AlbertT.J., WetzelT., McCullochJ.A.Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976), 30:2709. 2005.
BraddockM., HoustonP., CampbellC., AshcroftP.Born again bone: tissue engineering for bone repair. News Physiol Sci, 16:208. 2001.
14.
YamamotoM., TakahashiY., TabataY.Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials, 24:4375. 2003.
15.
YamamotoM., TabataY., IkadaY.Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed, 9:439. 1998.
16.
YangS.H., HsuC.K., WangK.C., HouS.M., LinF.H.Tricalcium phosphate and glutaraldehyde crosslinked gelatin incorporating bone morphogenetic protein—a viable scaffold for bone tissue engineering. J Biomed Mater Res B Appl Biomater, 74:468. 2005.
17.
SeehermanH., WozneyJ.M.Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev, 16:329. 2005.
18.
KempenD.H., LuL., HefferanT.E., CreemersL.B., MaranA., ClassicK.L., DhertW.J., YaszemskiM.J.Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials, 29:3245. 2008.
19.
KimH.D., ValentiniR.F.Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res, 59:573. 2002.
LuginbuehlV., MeinelL., MerkleH.P., GanderB.Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm, 58:197. 2004.
23.
RosenV.BMP and BMP inhibitors in bone. Ann N Y Acad Sci, 1068:19. 2006.
24.
TothJ.M., BodenS.D., BurkusJ.K., BaduraJ.M., PeckhamS.M., McKayW.F.Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976), 34:539. 2009.
25.
LiuY., EnggistL., KufferA.F., BuserD., HunzikerE.B.The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. Biomaterials, 28:2677. 2007.
HanB., HallF.L., NimniM.E.Refolding of a recombinant collagen-targeted TGF-beta2 fusion protein expressed in Escherichia coli. Protein Expr Purif, 11:169. 1997.
28.
HanB., PerelmanN., TangB., HallF., ShorsE.C., NimniM.E.Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J Orthop Res, 20:747. 2002.
29.
HallF.L., HanB., KunduR.K., YeeA., NimniM.E., GordonE.M.Phenotypic differentiation of TGF-beta1-responsive pluripotent premesenchymal prehematopoietic progenitor (P4 stem) cells from murine bone marrow. J Hematother Stem Cell Res, 10:261. 2001.
30.
AndradesJ.A., HanB., NimniM.E., ErtlD.C., SimpkinsR.J., ArrabalM.P., BecerraJ.A modified rhTGF-beta1 and rhBMP-2 are effective in initiating a chondro-osseous differentiation pathway in bone marrow cells cultured in vitro. Connect Tissue Res, 44:188. 2003.
31.
LiuH.W., ChenC.H., TsaiC.L., HsiueG.H.Targeted delivery system for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation. Bone, 39:825. 2006.
32.
SchmoekelH.G., WeberF.E., SchenseJ.C., GratzK.W., SchawalderP., HubbellJ.A.Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng, 89:253. 2005.
33.
TabataY.Tissue regeneration based on tissue engineering technology. Congenit Anom (Kyoto), 44:111. 2004.
34.
TabataY., HijikataS., IkadaY.Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels. J Controlled Release, 31:189. 1994.
35.
FerreiraJ.P., SasisekharanR., LouieO., LangerR.A study on the functional subunits of phospholipases A2 by enzyme immobilization. Biochem J, 303,Pt 2:527. 1994.
36.
TsujigiwaH., NagatsukaH., GunduzM., RodriguezA., RiveraR.S., LegerosR.Z., InoueM., NagaiN.Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells. J Biomed Mater Res A, 75:210. 2005.
37.
EhrbarM., RizziS.C., HlushchukR., DjonovV., ZischA.H., HubbellJ.A., WeberF.E., LutolfM.P.Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials, 28:3856. 2007.
38.
DemolliensA., BoucherC., DurocherY., JolicoeurM., BuschmannM.D., De CrescenzoG.Tyrosinase-catalyzed synthesis of a universal coil-chitosan bioconjugate for protein immobilization. Bioconjug Chem, 19:1849. 2008.
39.
ScuderiN., OnestiM.G., BistoniG., CeccarelliS., RotoloS., AngeloniA., MarcheseC.The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold. Biomaterials, 29:1620. 2008.
40.
EhrbarM., ZeisbergerS.M., RaeberG.P., HubbellJ.A., SchnellC., ZischA.H.The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials, 29:1720. 2008.
41.
Sakiyama-ElbertS.E., PanitchA., HubbellJ.A.Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J, 15:1300. 2001.
42.
KuwaharaK., YangZ., SlackG.C., NimniM.E., HanB.Cell delivery using an injectable and adhesive transglutaminase-gelatin gel. Tissue Eng Part C Methods, 16:609. 2010.
43.
BertoniF., BarbaniN., GiustiP., CiardelliG.Transglutaminase reactivity with gelatine: perspective applications in tissue engineering. Biotechnol Lett, 28:697. 2006.
44.
ItoA., MaseA., TakizawaY., ShinkaiM., HondaH., HataK., UedaM., KobayashiT.Transglutaminase-mediated gelatin matrices incorporating cell adhesion factors as a biomaterial for tissue engineering. J Biosci Bioeng, 95:196. 2003.
45.
YungC.W., WuL.Q., TullmanJ.A., PayneG.F., BentleyW.E., BarbariT.A.Transglutaminase crosslinked gelatin as a tissue engineering scaffold. J Biomed Mater Res A, 83:1039. 2007.
46.
ChenR.N., HoH.O., SheuM.T.Characterization of collagen matrices crosslinked using microbial transglutaminase. Biomaterials, 26:4229. 2005.
HanY.P., TuanT.L., WuH., HughesM., GarnerW.L.TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci, 114:131. 2001.
49.
HanB., TangB., NimniM.E.Quantitative and sensitive in vitro assay for osteoinductive activity of demineralized bone matrix. J Orthop Res, 21:648. 2003.
50.
GobinA.S., WestJ.L.Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. Biotechnol Prog, 19:1781. 2003.
51.
FolkJ.E.Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol, 54:1. 1983.
52.
FontanaA., SpolaoreB., MeroA., VeroneseF.M.Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev, 60:13. 2008.
53.
KahlemP., TerreC., GreenH., DjianP.Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc Natl Acad Sci U S A, 93:14580. 1996.
54.
OhtsukaT., OtaM., NioN., MotokiM.Comparison of substrate specificities of transglutaminases using synthetic peptides as acyl donors. Biosci Biotechnol Biochem, 64:2608. 2000.
55.
TaguchiS., NishihamaK.I., IgiK., ItoK., TairaH., MotokiM., MomoseH.Substrate specificity analysis of microbial transglutaminase using proteinaceous protease inhibitors as natural model substrates. J Biochem, 128:415. 2000.
56.
NickelJ., DreyerM.K., KirschT., SebaldW.The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg Am, 83-A,Suppl 1:S7. 2001.
57.
NamikiM., AkiyamaS., KatagiriT., SuzukiA., UenoN., YamajiN., RosenV., WozneyJ.M., SudaT.A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J Biol Chem, 272:22046. 1997.
58.
KirschT., NickelJ., SebaldW.BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J, 19:3314. 2000.
59.
LutolfM.P., Lauer-FieldsJ.L., SchmoekelH.G., MettersA.T., WeberF.E., FieldsG.B., HubbellJ.A.Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci U S A, 100:5413. 2003.
60.
LutolfM.P., WeberF.E., SchmoekelH.G., SchenseJ.C., KohlerT., MullerR., HubbellJ.A.Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol, 21:513. 2003.
61.
SeliktarD., ZischA.H., LutolfM.P., WranaJ.L., HubbellJ.A.MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res A, 68:704. 2004.
62.
KraehenbuehlT.P., FerreiraL.S., ZammarettiP., HubbellJ.A., LangerR.Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials, 30:4318. 2009.
63.
RaeberG.P., LutolfM.P., HubbellJ.A.Mechanisms of 3-D migration and matrix remodeling of fibroblasts within artificial ECMs. Acta Biomater, 3:615. 2007.
64.
ZischA.H., LutolfM.P., EhrbarM., RaeberG.P., RizziS.C., DaviesN., SchmokelH., BezuidenhoutD., DjonovV., ZillaP., HubbellJ.A.Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J, 17:2260. 2003.
65.
LluriG., JaworskiD.M.Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation. Muscle Nerve, 32:492. 2005.
66.
BlumenfeldI., SroujiS., PeledM., LivneE.Metalloproteinases (MMPs −2, −3) are involved in TGF-beta and IGF-1-induced bone defect healing in 20-month-old female rats. Arch Gerontol Geriatr, 35:59. 2002.
67.
KinohH., SatoH., TsunezukaY., TakinoT., KawashimaA., OkadaY., SeikiM.MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci, 109,Pt 5:953. 1996.
68.
MurphyG., LeeM.H.What are the roles of metalloproteinases in cartilage and bone damage?Ann Rheum Dis, 64,Suppl 4:iv44. 2005.
69.
OrbanJ.M., WilsonL.B., KofrothJ.A., El-KurdiM.S., MaulT.M., VorpD.A.Crosslinking of collagen gels by transglutaminase. J Biomed Mater Res A, 68:756. 2004.
